News

Prime Therapeutics taps Manmohan Mahajan as CFO, aiming to curb rising drug costs and expand affordability programs for health plans.

PBM, employer and pharmacy leaders at the Pharmacy Benefit Management Institute annual meeting said actionable data and real-time technology, not just transparency, are needed to control rising costs.

FDA expands accelerated approval of oral sevabertinib for first-line HER2-mutant lung cancer, offering targeted treatment with strong response rates versus standard chemotherapy.

Get the identity layer right, and every system in the health plan can answer the one question everything else depends on. Who is this person, and who are they connected to?

FDA approval brings Abbott’s TactiFlex Duo to AFib ablation, combining RF and pulsed field energy for tailored treatment in complex cases.

David Chen, Pharm.D., explores how formulary strategy and biosimilar adoption are reshaping affordability across health systems.

A new review says outcome tools like IHS4-55 and HiSQOL should replace or supplement HiSCR to better measure hidradenitis suppurativa treatment success.

Researchers and drug developers are targeting pathways that activate mast cells as a way to treat cholinergic urticaria and other forms of inducible urticaria.

Journavx (suzetrigine) helps 76% of common-surgery patients avoid rescue opioids, signaling a new non-opioid option for acute pain.

Women with endometriosis had an overall 46% higher risk of developing Type 2 diabetes. The association was strongest among premenopausal women and women without obesity, groups not traditionally considered high-risk for Type 2 diabetes.

In this discussion, Tiffany Phung, Pharm.D., CSP, director of specialty pharmacy value, trade relations and market access at UC Davis Health, explores the challenges facing health system specialty pharmacies and how data-driven collaboration is shaping the future of patient care.

Part D enrollment has shifted: standalone plan offerings are down 22%, while special needs plans grew 21%, reshaping competition among fewer, larger sponsors nationally, finds an analysis by IPD Analytics.

Luis Ortiz, M.D., of Johns Hopkins All Children's Hospital, explains the subtle signs of childhood narcolepsy that parents often overlook.

Pediatric sleep specialist Luis Enrique Ortiz, M.D., opens up about living with Type 1 narcolepsy with cataplexy, the long road to diagnosis and how the condition has shaped both his career and personal life.

Medicare’s GLP-1 Bridge program offers eligible Part D beneficiaries select GLP-1s for weight loss at $50/month, outside Part D, pending BALANCE model.

Shingrix (recombinant shingles vaccine) links to 9% lower cardiovascular disease burden in older adults over seven years, strengthening vaccination value beyond shingles prevention.

A Swedish registry study of 58,641 patients found lower education levels were linked to higher mortality after hip fracture surgery.

A University of Pennsylvania study found that GLP-1 users with Type 2 diabetes had 37% to 68% higher hair loss rates than patients taking other diabetes medications.

A Johns Hopkins trial found low-dose hydrocortisone improved attention and verbal learning in women with HIV, with gains sustained over several weeks.

University of Utah Health researchers have shown that a protein involved in cancer growth also plays a role in whether a fatty liver progresses to MASH.

Mimrylo is available now to treat adults with polycythemia vera, a blood cancer that causes the overproduction of red blood cells. It has a list price of $4,200 per vial.

As artificial intelligence agents learn to improve autonomously, the humans who must use and regulate such tools find themselves behind the curve.

Funding from the Rural Health Transformation Program is beginning to flow to the states. The purpose is larger, but some say its success should be measured by whether it preserves access to care at rural hospitals.

VESALIUS-CV shows Repatha (evolocumab) cuts all-cause death 20% in high-risk CVD patients, preventing future stroke and heart attack.

Mounjaro is now approved for two indications: to improve blood sugar in patients with Type 2 diabetes and to lower the major adverse cardiovascular events.

JAMA Health Forum finds Medicare Advantage members with new complex diagnoses increasingly switch to traditional Medicare, highlighting MediGap barriers, state protections, and plan limits.

People may not be fully aware of added cost exposures if they shift to bronze Affordable Care (ACA) plans, says Margaret A. Murray, M.P.A., CEO of the Association for Community Health Plans. Murray says the nonnetwork plans that the Trump administration is promoting will result in underinsurance.

Gilead's Bixlenvo, the smallest once-daily HIV pill yet, has been approved by the FDA for virologically suppressed adults on complex regimens.